Non-US trials

Last updated: Tue Jun 04 18:36:34 PDT 2013
  1. Currently-recruiting dendritic vaccine trials (26)
  2. Enrolling-by-invitation dendritic vaccine trials (0)
  3. Active-but-not-recruiting dendritic vaccine trials (15)
  4. Completed dendritic vaccine trials (20)
  5. Not-yet-recruiting dendritic vaccine trials (2)

Currently-recruiting dendritic vaccine trials (26)

# Study
1

Safety Study of a Cell-based Cancer Vaccine in Melanoma

Status Currently-recruiting
Phase Unspecified
Conditions Melanoma, Effects of Immunotherapy, Tumor Vaccines
Start date May 2013 End date November 2016
Study type INTERVENTIONAL
Interventions GeniusVac-Mel4
NCT number NCT01863108

Go to top of page

2

Sipuleucel-T Manufacturing Demonstration Study

Status Currently-recruiting
Phase Unspecified
Conditions Prostate Neoplasms, Neoplasms, Prostate, Prostatic Cancer, Neoplasms, Prostatic, Prostate Cancer, Cancer of the Prostate, Cancer of Prostate
Start date June 2012 End date January 2014
Study type INTERVENTIONAL
Interventions sipuleucel-T
NCT number NCT01477749

Go to top of page

3

Study of DC Vaccination Against Glioblastoma

Status Currently-recruiting
Phase Unspecified
Conditions Glioblastoma Multiforme, Neoplasms, Glioma
Start date March 2012 End date July 2014
Study type INTERVENTIONAL
Interventions Radiotherapy, Chemotherapy, blank placebo, surgery, DC vaccination
NCT number NCT01567202

Go to top of page

4

A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Metastatic Renal Cell Carcinoma
Start date February 2012 End date June 2013
Study type INTERVENTIONAL
Interventions Combig-DC (allogeneic dendritic cells) Cancer Vaccine
NCT number NCT01525017

Go to top of page

5

To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore

Status Currently-recruiting
Phase Unspecified
Conditions Anonymous Donors at Blood Donation Center (NUH)
Start date January 2012 End date Unspecified
Study type OBSERVATIONAL
Interventions
NCT number NCT01570439

Go to top of page

6

Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Prostatic Neoplasms
Start date October 2011 End date October 2012
Study type INTERVENTIONAL
Interventions mRNA transfected dendritic cell, Docetaxel
NCT number NCT01446731

Go to top of page

7

Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Colorectal Neoplasms
Start date August 2011 End date August 2014
Study type INTERVENTIONAL
Interventions Supportive treatment, dendritic cell vaccine
NCT number NCT01413295

Go to top of page

8

Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients

Status Currently-recruiting
Phase Unspecified
Conditions Recurrent Epithelial Ovarian Cancer
Start date April 2011 End date April 2022
Study type INTERVENTIONAL
Interventions DC-006 vaccine
NCT number NCT01334047

Go to top of page

9

Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer

Status Currently-recruiting
Phase Unspecified
Conditions Stage III Breast Cancer, Stage II Breast Cancer
Start date February 2011 End date December 2013
Study type INTERVENTIONAL
Interventions Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
NCT number NCT01431196

Go to top of page

10

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Status Currently-recruiting
Phase Unspecified
Conditions Wilm’s Tumor, Ewing’s Sarcoma, Glioma, Neuroblastoma, Retinoblastoma
Start date February 2011 End date September 2013
Study type INTERVENTIONAL
Interventions racotumomab
NCT number NCT01598454

Go to top of page

11

Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma

Status Currently-recruiting
Phase Unspecified
Conditions Colorectal Carcinoma, Hepatic Metastasis
Start date November 2010 End date June 2014
Study type INTERVENTIONAL
Interventions Dendritic cells vaccine
NCT number NCT01348256

Go to top of page

12

Vaccine Therapy in Curative Resected Prostate Cancer Patients

Status Currently-recruiting
Phase Unspecified
Conditions Prostate Cancer
Start date September 2010 End date September 2021
Study type INTERVENTIONAL
Interventions dendritic cell vaccine
NCT number NCT01197625

Go to top of page

13

Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients

Status Currently-recruiting
Phase Unspecified
Conditions Melanoma
Start date September 2010 End date Unspecified
Study type INTERVENTIONAL
Interventions Theravac
NCT number NCT01331915

Go to top of page

14

Dendritic Cell Cancer Vaccine for High-grade Glioma

Status Currently-recruiting
Phase Unspecified
Conditions Glioblastoma Multiforme
Start date March 2010 End date December 2012
Study type INTERVENTIONAL
Interventions Temozolomide, Surgery, Radiotherapy, Trivax, Temozolomide, Surgery, Radiotherapy
NCT number NCT01213407

Go to top of page

15

Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes

Status Currently-recruiting
Phase Unspecified
Conditions Non Small Cell Lung Cancer
Start date December 2009 End date December 2014
Study type INTERVENTIONAL
Interventions Dex2
NCT number NCT01159288

Go to top of page

16

Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma

Status Currently-recruiting
Phase Unspecified
Conditions Breast Cancer, Malignant Melanoma
Start date September 2009 End date September 2012
Study type INTERVENTIONAL
Interventions DC vaccine
NCT number NCT00978913

Go to top of page

17

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma

Status Currently-recruiting
Phase Unspecified
Conditions Renal Cell Carcinoma
Start date March 2009 End date December 2015
Study type INTERVENTIONAL
Interventions DC-CIK, IL-2/IFN-α
NCT number NCT00862303

Go to top of page

18

Plasmacytoid Dendritic Cell Vaccines in Metastatic Melanoma Patients

Status Currently-recruiting
Phase Unspecified
Conditions
Start date February 2008 End date December 2013
Study type INTERVENTIONAL
Interventions
NCT number NCT01690377

Go to top of page

19

Generation of Dendritic Cell Precursors From Cord Blood Stem Cells

Status Currently-recruiting
Phase Unspecified
Conditions Normal Full-Term Deliveries
Start date January 2007 End date December 2010
Study type INTERVENTIONAL
Interventions Normal full-term deliveries
NCT number NCT00731744

Go to top of page

20

Dendritic Cell Vaccine in HIV-1 Infection

Status Currently-recruiting
Phase Unspecified
Conditions HIV Infections
Start date November 2006 End date December 2009
Study type INTERVENTIONAL
Interventions dendritic cell vaccine
NCT number NCT00402142

Go to top of page

21

Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection

Status Currently-recruiting
Phase Unspecified
Conditions Neoplasms
Start date October 2006 End date December 2009
Study type INTERVENTIONAL
Interventions Immune profiling and DC vaccine
NCT number NCT00521287

Go to top of page

22

The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2

Status Currently-recruiting
Phase Unspecified
Conditions Metastatic Melanoma
Start date December 2005 End date Unspecified
Study type INTERVENTIONAL
Interventions Immunotherapy treatment for melanoma
NCT number NCT00279058

Go to top of page

23

Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

Status Currently-recruiting
Phase Unspecified
Conditions Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Lymphoma
Start date September 2003 End date Unspecified
Study type INTERVENTIONAL
Interventions autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine, autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine
NCT number NCT00937183

Go to top of page

24

Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma

Status Currently-recruiting
Phase Unspecified
Conditions Melanoma (Skin)
Start date July 2003 End date Unspecified
Study type INTERVENTIONAL
Interventions recombinant MAGE-3.1 antigen, survivin antigen, MART-1 antigen, keyhole limpet hemocyanin, therapeutic autologous dendritic cells
NCT number NCT00074230

Go to top of page

25

Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)

Status Currently-recruiting
Phase Unspecified
Conditions Cervical Cancer
Start date January 2003 End date March 2006
Study type INTERVENTIONAL
Interventions HPV16 E7 peptide-pulsed autologous DCs
NCT number NCT00155766

Go to top of page

26

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

Status Currently-recruiting
Phase Unspecified
Conditions Melanoma (Skin)
Start date October 2002 End date Unspecified
Study type INTERVENTIONAL
Interventions dendritic cell-idiotype-keyhole limpet hemocyanin vaccine, HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine, autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine, autologous melanoma lysate-pulsed autologous dendritic cell vaccine, flow cytometry, adjuvant therapy, HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine
NCT number NCT01082198

Go to top of page

Active-but-not-recruiting dendritic vaccine trials (15)

# Study
1

Proteome-based Personalized Immunotherapy of Glioblastoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions
Start date December 2012 End date December 2017
Study type INTERVENTIONAL
Interventions
NCT number NCT01759810

Go to top of page

2

Proteome-based Immunotherapy of Brain Metastases From Breast Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Neoplasm Metastasis
Start date December 2012 End date December 2017
Study type INTERVENTIONAL
Interventions Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes, Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes
NCT number NCT01782274

Go to top of page

3

Proteome-based Immunotherapy of Lung Cancer Brain Metastases

Status Active-but-not-recruiting
Phase Unspecified
Conditions Neoplasm Metastasis
Start date December 2012 End date December 2017
Study type INTERVENTIONAL
Interventions Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes, Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
NCT number NCT01782287

Go to top of page

4

Safety of Active Immunotherapy in Subjects With Ovarian Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Ovarian Epithelial Cancer
Start date September 2010 End date April 2013
Study type INTERVENTIONAL
Interventions Procure
NCT number NCT01456065

Go to top of page

5

Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma
Start date April 2010 End date January 2013
Study type INTERVENTIONAL
Interventions autologous dendritic cell vaccine
NCT number NCT01530698

Go to top of page

6

A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma
Start date December 2009 End date September 2014
Study type INTERVENTIONAL
Interventions TriMix-DC
NCT number NCT01066390

Go to top of page

7

Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection

Status Active-but-not-recruiting
Phase Unspecified
Conditions Glioblastoma Multiforme
Start date October 2009 End date June 2014
Study type INTERVENTIONAL
Interventions Autologous Dendritic Cells
NCT number NCT01006044

Go to top of page

8

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Metastatic Malignant Melanoma
Start date August 2009 End date August 2020
Study type INTERVENTIONAL
Interventions Temozolomide, Dendritic cells – transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion
NCT number NCT00961844

Go to top of page

9

Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma
Start date June 2009 End date June 2015
Study type INTERVENTIONAL
Interventions autologous dendritic cell vaccination
NCT number NCT00940004

Go to top of page

10

Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Glioblastoma, Brain Tumor
Start date January 2009 End date October 2015
Study type INTERVENTIONAL
Interventions Dendritic cell vaccine with mRNA from tumor stem cells
NCT number NCT00846456

Go to top of page

11

Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer

Status Active-but-not-recruiting
Phase Unspecified
Conditions Head and Neck Cancer
Start date November 2007 End date Unspecified
Study type INTERVENTIONAL
Interventions celecoxib, laboratory biomarker analysis, immunoenzyme technique, flow cytometry, Ad5F35-LMP1/LMP2-transduced autologous dendritic cells
NCT number NCT00589186

Go to top of page

12

Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells

Status Active-but-not-recruiting
Phase Unspecified
Conditions Carcinoma, Hepatocellular
Start date June 2005 End date June 2006
Study type INTERVENTIONAL
Interventions DC vaccine
NCT number NCT00327496

Go to top of page

13

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma (Skin)
Start date April 2005 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells, autologous tumor cell vaccine
NCT number NCT00126685

Go to top of page

14

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma (Skin)
Start date October 2002 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells, recombinant CD40-ligand, denileukin diftitox
NCT number NCT00056134

Go to top of page

15

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Status Active-but-not-recruiting
Phase Unspecified
Conditions Melanoma (Skin)
Start date October 2002 End date Unspecified
Study type INTERVENTIONAL
Interventions recombinant CD40-ligand, therapeutic autologous dendritic cells
NCT number NCT00053391

Go to top of page

Completed dendritic vaccine trials (20)

# Study
1

p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer

Status Completed
Phase Unspecified
Conditions Ovarian Cancer
Start date October 2008 End date July 2009
Study type INTERVENTIONAL
Interventions P53-SLP vaccine, cyclophosphamide
NCT number NCT00844506

Go to top of page

2

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Status Completed
Phase Unspecified
Conditions Leukemia
Start date June 2008 End date Unspecified
Study type INTERVENTIONAL
Interventions therapeutic autologous dendritic cells
NCT number NCT00963521

Go to top of page

3

Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection

Status Completed
Phase Unspecified
Conditions HIV Infections
Start date January 2007 End date October 2008
Study type INTERVENTIONAL
Interventions Peptides on autologous Dendritic Cells
NCT number NCT00856154

Go to top of page

4

Dendritic Cells in Lung Cancer

Status Completed
Phase Unspecified
Conditions Non Small Cell Lung Cancer
Start date December 2006 End date November 2009
Study type INTERVENTIONAL
Interventions Allogeneic Tumour Lysate (MelCancerVac)
NCT number NCT00442754

Go to top of page

5

Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer

Status Completed
Phase Unspecified
Conditions Prostatic Cancer
Start date July 2006 End date May 2010
Study type INTERVENTIONAL
Interventions Autologous Dendritic Cell
NCT number NCT01171729

Go to top of page

6

Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission

th width=’25%’>Start date
Status Completed
Phase Unspecified
Conditions Acute Myeloid Leukemia (AML)
March 2005 End date December 2008
Study type INTERVENTIONAL
Interventions injection of antigen-loaded cultured dendritic cells
NCT number NCT00834002

Go to top of page

7

Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)

Status Completed
Phase Unspecified
Conditions Metastatic Breast Cancer
Start date January 2005 End date May 2012
Study type INTERVENTIONAL
Interventions AdHer-2/neu transduced dendritic cells
NCT number NCT00162929

Go to top of page

8

Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells

Status Completed
Phase Unspecified
Conditions Melanoma
Start date October 2004 End date December 2005
Study type INTERVENTIONAL
Interventions DC/Apo-Nec
NCT number NCT00515983

Go to top of page

9

Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2

Status Completed
Phase Unspecified
Conditions Breast Neoplasms
Start date October 2004 End date May 2012
Study type INTERVENTIONAL
Interventions CD34+ derived DCs
NCT number NCT00197522

Go to top of page

10

Dendritic Cell Based Therapy of Malignant Melanoma

Status Completed
Phase Unspecified
Conditions Advanced Melanoma
Start date September 2004 End date April 2010
Study type INTERVENTIONAL
Interventions tumor antigen loaded autologous dendritic cells
NCT number NCT00197912

Go to top of page

11

Dendritic Cell Based Therapy of Renal Cell Carcinoma

Status Completed
Phase Unspecified
Conditions Advanced Renal Cell Carcinoma
Start date September 2004 End date October 2010
Study type INTERVENTIONAL
Interventions tumor antigen loaded autologous dendritic cells
NCT number NCT00197860

Go to top of page

12

Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

Status Completed
Phase Unspecified
Conditions Melanoma Stage III or IV
Start date April 2004 End date Unspecified
Study type INTERVENTIONAL
Interventions autologous dendritic cell vaccine
NCT number NCT00243529

Go to top of page

13

Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients

Status Completed
Phase Unspecified
Conditions Melanoma
Start date March 2004 End date October 2005
Study type INTERVENTIONAL
Interventions Dendritic cells, Daclizumab
NCT number NCT00847106

Go to top of page

14

Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients

Status Completed
Phase Unspecified
Conditions Liver Metastases, Colorectal Cancer
Start date December 2003 End date November 2010
Study type INTERVENTIONAL
Interventions CEA-loaded dendritic cell vaccine
NCT number NCT00228189

Go to top of page

15

Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

Status Completed
Phase Unspecified
Conditions Plasmocytoma, Multiple Myeloma
Start date March 2002 End date March 2004
Study type INTERVENTIONAL
Interventions autologous idiotype-protein pulsed dendritic cells
NCT number NCT00988312

Go to top of page

16

Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma

Status Completed
Phase Unspecified
Conditions Multiple Myeloma and Plasma Cell Neoplasm
Start date August 2001 End date November 2007
Study type INTERVENTIONAL
Interventions reverse transcriptase-polymerase chain reaction, polymerase chain reaction, laboratory biomarker analysis, idiotype-pulsed autologous dendritic cell vaccine APC8020, flow cytometry, aldesleukin, recombinant interferon gamma
NCT number NCT00616720

Go to top of page

17

Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection

Status Completed
Phase Unspecified
Conditions Melanoma Stage III or IV
Start date September 1999 End date Unspecified
Study type INTERVENTIONAL
Interventions Peptide-pulsed dendritic cells
NCT number NCT00243594

Go to top of page

18

Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma

Status Completed
Phase Unspecified
Conditions Malignant Melanoma
Start date End date Unspecified
Study type INTERVENTIONAL
Interventions Dendritic Cells (DC) malignant melanoma
NCT number NCT01278940

Go to top of page

19

Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer

Status Completed
Phase Unspecified
Conditions Prostate Cancer
Start date End date Unspecified
Study type INTERVENTIONAL
Interventions Dendritic Cells (DC) prostate
NCT number NCT01278914

Go to top of page

20

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Status Completed
Phase Unspecified
Conditions Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Start date End date Unspecified
Study type INTERVENTIONAL
Interventions dendritic cell-gp100-MART-1 antigen vaccine, sargramostim
NCT number NCT00019890

Go to top of page

Not-yet-recruiting dendritic vaccine trials (2)

# Study
1

Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission

Status Not-yet-recruiting
Phase Unspecified
Conditions
Start date October 2012 End date Unspecified
Study type INTERVENTIONAL
Interventions
NCT number NCT01686334

Go to top of page

2

Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults

Status Not-yet-recruiting
Phase Unspecified
Conditions HIV Infections
Start date End date Unspecified
Study type INTERVENTIONAL
Interventions DermaVir patch, Placebo patch
NCT number NCT00614640

Go to top of page

%d bloggers like this: